Streamlining Infusion Therapy Prior Authorization for Pulmonology

Navigating Infusion Therapy prior authorization for pulmonology patients requires precision, especially for high-cost biologics and site-of-service considerations.

For revenue cycle directors and prior authorization coordinators in pulmonology, the complexities of securing approvals for infused specialty drugs can significantly impact patient care timelines and financial outcomes. Klivira provides a robust solution to automate and accelerate the prior authorization process, addressing the unique challenges of respiratory medicine.

The Pulmonology Landscape for Infusion Therapy

Infusion therapy in pulmonology primarily involves high-cost specialty drugs for conditions like severe asthma and idiopathic pulmonary fibrosis (IPF). These include biologics such as omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab for asthma, and antifibrotics like pirfenidone and nintedanib for IPF. The site-of-service for these infusions—whether in-office, outpatient hospital department (HOPD), or home—is a critical dimension of prior authorization review.

Key Prior Authorization Triggers in Pulmonology Infusion

Prior authorization for pulmonology infusions is typically triggered by the initiation or re-authorization of specific high-cost medications. Beyond biologics and antifibrotics, certain COPD specialty drugs and severe asthma maintenance therapies may also require PA, particularly when step-therapy protocols are in place. Lung transplant evaluation and subsequent immunosuppression regimens also fall into this category, demanding meticulous documentation.

Critical Documentation for Pulmonology Infusion PA

Eosinophil counts (peripheral or sputum) for IL-5 targeting asthma biologics.
Evidence of prior controller therapy at maximum dose, aligning with GINA guidelines for asthma.
Detailed exacerbation history and severity classification for severe asthma.
Pulmonary function testing (PFTs) to support diagnosis and disease severity.
Adherence to ATS guidelines for respiratory conditions and GOLD guidelines for COPD.

Common Denial Reasons and Mitigation Strategies

Denials for pulmonology infusion prior authorizations frequently stem from unmet step-therapy requirements, particularly for asthma biologics where payers often require a trial of high-dose ICS-LABA. Eosinophil-count thresholds not being met for IL-5 targeting biologics, or insufficient evidence of conservative therapy for IPF antifibrotics, are also prevalent denial reasons. Klivira's platform incorporates GINA/GOLD/ATS-aware step-therapy logic and automates the collection of required documentation to proactively address these issues.

Klivira's Role in Pulmonology Infusion PA Automation

Klivira integrates with EMRs to streamline the submission of critical clinical data, including eosinophil counts and treatment histories, directly to payer portals and ePA channels. Our system is designed to navigate complex payer-specific policies and step-therapy protocols for asthma biologics and other infused respiratory therapies. This automation minimizes manual effort, accelerates approval times, and reduces denials, ensuring patients receive timely access to essential infusion treatments.

Frequently asked questions

Which pulmonology conditions commonly require infusion therapy prior authorization?

Infusion therapy prior authorization in pulmonology is common for severe asthma, requiring biologics like Dupixent or Nucala, and for idiopathic pulmonary fibrosis (IPF) with antifibrotics such as Esbriet or Ofev. Certain COPD specialty drugs and lung transplant immunosuppression regimens also frequently require PA.

How does site-of-service impact infusion therapy prior authorization for pulmonology?

Site-of-service review is a significant factor in pulmonology infusion PA, as payers often scrutinize the appropriateness of home, in-office, or outpatient hospital department (HOPD) settings. Documentation justifying the chosen site, considering patient stability and safety, is crucial for approval.

What specific clinical guidelines are relevant for pulmonology infusion PA?

Key clinical guidelines relevant for pulmonology infusion PA include the Global Initiative for Asthma (GINA) for asthma management, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) for COPD, and various American Thoracic Society (ATS) guidelines for respiratory conditions. Adherence to these guidelines is often a payer requirement.

How does Klivira help with re-authorization for pulmonology infusion therapies?

Klivira automates the re-authorization workflow for pulmonology infusion therapies by tracking approval expirations and proactively prompting for updated clinical documentation. This ensures continuous coverage for maintenance therapies like asthma biologics, preventing gaps in care due to lapsed authorizations.

Can Klivira integrate with our EMR for pulmonology infusion PA data?

Yes, Klivira is designed to integrate with major EMR systems using standards like SMART on FHIR. This integration allows for seamless extraction of relevant patient data, such as eosinophil counts, PFT results, and medication histories, directly into the prior authorization request, reducing manual data entry and errors.